Rt Hon JACINDA ARDERN: I can say that we're working in earnest across a number of different strategies. When we have more detail that I'm willing to share, we will absolutely share it. But, as I say, we're already thinking in advance, if in the eventuality we're unable to meet that extra demand, what we would do around the existing supply that we have. Keep in mind we've of course always had deliveries coming in of Pfizer on a weekly basis, but they've been in the order of 300,000, when we are currently seeing demand of over 500,000—demand that we have helped create by putting in extra surge capacity.